Tejas Savant
Stock Analyst at Morgan Stanley
(2.33)
# 1,428
Out of 4,412 analysts
181
Total ratings
43.65%
Success rate
-3.54%
Average return
Main Sectors:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLK Olink Holding AB (publ) | Maintains: Equal-Weight | $26 | $22.84 | +13.84% | 11 | Mar 26, 2024 | |
| VCYT Veracyte | Maintains: Underweight | $22 → $21 | $19.31 | +8.75% | 7 | Feb 26, 2024 | |
| HOLX Hologic | Maintains: Equal-Weight | $86 → $82 | $75.98 | +7.92% | 7 | Nov 13, 2023 | |
| NTRA Natera | Maintains: Overweight | $70 → $68 | $91.66 | -25.81% | 7 | Nov 10, 2023 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Overweight | $12 → $11 | $7.70 | +42.86% | 10 | Nov 9, 2023 | |
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $8 → $7 | $5.76 | +21.53% | 8 | Nov 9, 2023 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $16 → $17 | $14.14 | +20.23% | 11 | Nov 8, 2023 | |
| IQV IQVIA Holdings | Maintains: Overweight | $240 → $225 | $234.88 | -4.21% | 8 | Nov 3, 2023 | |
| AVTR Avantor | Maintains: Overweight | $24 → $22 | $23.94 | -8.10% | 12 | Oct 30, 2023 | |
| TMO Thermo Fisher | Maintains: Overweight | $600 → $545 | $573.60 | -4.99% | 9 | Oct 26, 2023 | |
| PACB Pacific Biosciences of California | Maintains: Equal-Weight | $13 → $10 | $1.47 | +580.27% | 6 | Oct 24, 2023 | |
| AKYA Akoya Biosciences | Maintains: Overweight | $15 → $8 | $3.80 | +110.53% | 8 | Oct 24, 2023 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $13 → $10 | $2.60 | +284.62% | 9 | Oct 24, 2023 | |
| CTLT Catalent | Maintains: Overweight | $52 → $55 | $55.92 | -1.65% | 10 | Aug 30, 2023 | |
| CYRX Cryoport | Initiates: Equal-Weight | $16 | $16.38 | -2.32% | 1 | Aug 17, 2023 | |
| TXG 10x Genomics | Reiterates: Overweight | $65 | $27.59 | +135.59% | 8 | Aug 7, 2023 | |
| NAUT Nautilus Biotechnology | Reiterates: Equal-Weight | $6 | $2.49 | +140.96% | 3 | Aug 3, 2023 | |
| SOPH SOPHiA GENETICS | Maintains: Overweight | $11 → $10 | $5.03 | +98.81% | 8 | May 10, 2023 | |
| RPID Rapid Micro Biosystems | Reiterates: Equal-Weight | $2.75 | $0.95 | +190.82% | 5 | Mar 7, 2023 | |
| PSNL Personalis | Maintains: Equal-Weight | $11 → $5 | $1.27 | +295.26% | 4 | Feb 27, 2023 | |
| SEER Seer, Inc. | Maintains: Equal-Weight | $11 → $10 | $1.91 | +423.56% | 9 | Feb 21, 2023 | |
| GH Guardant Health | Maintains: Overweight | $80 → $73 | $17.35 | +320.75% | 7 | Feb 21, 2023 | |
| ILMN Illumina | Maintains: Equal-Weight | $240 → $225 | $122.28 | +84.00% | 4 | Nov 7, 2022 | |
| DNA Ginkgo Bioworks Holdings | Initiates: Equal-Weight | $5 | $0.86 | +481.33% | 1 | Oct 4, 2022 | |
| HLTH Cue Health | Maintains: Equal-Weight | $10 → $8 | $0.14 | +5,573.76% | 4 | Aug 11, 2022 | |
| CRL Charles River Laboratories International | Downgrades: Equal-Weight | $350 → $250 | $229.03 | +9.16% | 1 | Aug 4, 2022 | |
| BDSX Biodesix | Maintains: Equal-Weight | $7 → $5 | $1.24 | +304.86% | 3 | May 12, 2022 |
Olink Holding AB (publ)
Mar 26, 2024
Maintains: Equal-Weight
Price Target: $26
Current: $22.84
Upside: +13.84%
Veracyte
Feb 26, 2024
Maintains: Underweight
Price Target: $22 → $21
Current: $19.31
Upside: +8.75%
Hologic
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $86 → $82
Current: $75.98
Upside: +7.92%
Natera
Nov 10, 2023
Maintains: Overweight
Price Target: $70 → $68
Current: $91.66
Upside: -25.81%
Maravai LifeSciences Holdings
Nov 9, 2023
Maintains: Overweight
Price Target: $12 → $11
Current: $7.70
Upside: +42.86%
Cytek Biosciences
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $5.76
Upside: +21.53%
NeoGenomics
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $14.14
Upside: +20.23%
IQVIA Holdings
Nov 3, 2023
Maintains: Overweight
Price Target: $240 → $225
Current: $234.88
Upside: -4.21%
Avantor
Oct 30, 2023
Maintains: Overweight
Price Target: $24 → $22
Current: $23.94
Upside: -8.10%
Thermo Fisher
Oct 26, 2023
Maintains: Overweight
Price Target: $600 → $545
Current: $573.60
Upside: -4.99%
Pacific Biosciences of California
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $1.47
Upside: +580.27%
Akoya Biosciences
Oct 24, 2023
Maintains: Overweight
Price Target: $15 → $8
Current: $3.80
Upside: +110.53%
Adaptive Biotechnologies
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $2.60
Upside: +284.62%
Catalent
Aug 30, 2023
Maintains: Overweight
Price Target: $52 → $55
Current: $55.92
Upside: -1.65%
Cryoport
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $16.38
Upside: -2.32%
10x Genomics
Aug 7, 2023
Reiterates: Overweight
Price Target: $65
Current: $27.59
Upside: +135.59%
Nautilus Biotechnology
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.49
Upside: +140.96%
SOPHiA GENETICS
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $5.03
Upside: +98.81%
Rapid Micro Biosystems
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $0.95
Upside: +190.82%
Personalis
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $1.27
Upside: +295.26%
Seer, Inc.
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.91
Upside: +423.56%
Guardant Health
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $17.35
Upside: +320.75%
Illumina
Nov 7, 2022
Maintains: Equal-Weight
Price Target: $240 → $225
Current: $122.28
Upside: +84.00%
Ginkgo Bioworks Holdings
Oct 4, 2022
Initiates: Equal-Weight
Price Target: $5
Current: $0.86
Upside: +481.33%
Cue Health
Aug 11, 2022
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $0.14
Upside: +5,573.76%
Charles River Laboratories International
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $229.03
Upside: +9.16%
Biodesix
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.24
Upside: +304.86%